Literature DB >> 344798

A newly described activity of guinea pig IgG1 antibodies: transfer of cutaneous basophil reactions.

J D Haynes, R W Rosenstein, P W Askenase.   

Abstract

Hapten-specific delayed time course skin reactions containing predominant accumulations of basophils and eosinophils were elicited in newborn guinea pigs after i.v. transfer of small amounts of oxazolone immune serum. The immune serum was fractionated by column chromatography procedures, and the fractions were examined for their ability in transferring this form of cutaneous basophil hypersensitivity (CBH). Only the 7S IgG-containing peak from Sephadex G-200 columns, and only the IgG1-containing fractions from DEAE columns, transferred CBH. An affinity column of bound oxazolone removed the activity from immune serum, and it could be recovered from the column by eluting with soluble oxazolone. About 35 microgram of purified IgG1 anti-oxazolone antibody could systemically transfer CBH reactivity. An immunoadsorbant column of anti-IgG1 removed this activity, but a column of anti-IgG2 did not. None of the procedures were able to separate activity in transferring CBH from passive cutaneous anaphylactic (PCA) activity classically associated with guinea pig IgG1 antibody. IgG1 from 8-day immune and 31-day hyperimmune donors were both effective. The average association constant of 8-day antibody was 8 X 10(-4) M-1. Transfer of cutaneous basophil reactions can be mediated by low affinity serum 7S IgG1 antibody.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 344798

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Immunity to schistosomiasis mansoni in guinea-pigs vaccinated with radiation-attenuated cercariae: I. Humoral responses against skin-stage schistosomula.

Authors:  J R Gordon; D J McLaren
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

2.  Inflammatory response linked to oxazolone-indued cutaneous basophil hypersensitivity: effect of different immunomodulator and anti-inflammatory drugs.

Authors:  J Bure; F Degrand
Journal:  Agents Actions       Date:  1979-12

3.  The mediation of tissue eosinophilia in hypersensitivity reactions. V. Comparative study of tissue eosinophilia in the skin lesions of local and systemic passive cutaneous anaphylactic reactions.

Authors:  M Hirashima; K Tashiro; Y Hirotsu; H Hayashi
Journal:  Immunology       Date:  1983-09       Impact factor: 7.397

Review 4.  Basophils in human disease.

Authors:  E B Mitchell; P W Askenase
Journal:  Clin Rev Allergy       Date:  1983-09

5.  Dissociation of erythema and basophil accumulation in Jones-Mote type hypersensitivity in the guinea-pig.

Authors:  S Yoshida; K Nomoto; K Himeno
Journal:  Br J Exp Pathol       Date:  1979-12

6.  Cutaneous basophil-associated resistance to ectoparasites (ticks). I. Transfer with immune serum or immune cells.

Authors:  P W Askenase; B G Bagnall; M J Worms
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

7.  Receptor-specific mediation by immunoglobulin E of antigen-induced contraction of tracheal and lung parenchymal strips isolated from the guinea pig.

Authors:  F M Graziano; L Gundersen; L A Larson; P Harley; C K Buckner
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

8.  An early component of delayed-type hypersensitivity mediated by T cells and mast cells.

Authors:  H van Loveren; R Meade; P W Askenase
Journal:  J Exp Med       Date:  1983-05-01       Impact factor: 14.307

9.  The role of basophils and mast cells in cutaneous basophil hypersensitivity reaction.

Authors:  T Kishimoto; R Soda; K Takahashi; I Kimura
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

10.  B cell-dependent T cell responses: IgM antibodies are required to elicit contact sensitivity.

Authors:  Ryohei F Tsuji; Marian Szczepanik; Ivana Kawikova; Vipin Paliwal; Regis A Campos; Atsuko Itakura; Moe Akahira-Azuma; Nicole Baumgarth; Leonore A Herzenberg; Philip W Askenase
Journal:  J Exp Med       Date:  2002-11-18       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.